Global Epigenetics Market was Valued at US$ 1.2 Bn in 2018, Owing to Rising Support from the Government & Funding from Public and Private Bodies
“The Global Epigenetics Market was valued at US$ 1.2 Mn in 2018 and is expected to grow at a significant CAGR over six years forecast period 2019-2025 owing to increasing prevalence of cancer and declining sequencing costs and time”
Precision Business Insights (PBI) in its report titled “Global Epigenetics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2018 and Forecast 2019-2025” assesses the market performance over six years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.
The global epigenetics market was valued at US$ 1.2 Mn in 2018 and growing at a CAGR of 12.5% over the forecast period owing to lessening sequencing costs, growing research activities, sponsorships for epigenetics research, increasing occurrence of cancer and rising applications of epigenetics in non-oncology diseases. Intensifying application areas of epigenetics in non-oncology diseases, personalized medicine, and target therapy are anticipated to create lucrative opportunities for the market players over the forecast period. Rising prevalence of cancer is the major parameter driving the growth of the market. For instance, According to ACS, in the US, the number of new cancer cases (excluding carcinoma in situ of any site) is projected to rise to 1,688,780 in 2017 from 1,685,210 in 2016, while the total number of cancer-related deaths will increase to 600,920 from 595,690 during the same period. High cost of instruments and dearth of trained professionals are expected to hamper the growth of the market over the forecast period.
Global epigenetics market segmented on the basis of product, application, technology, end user, and region.
Request Sample Report:
Oncology segment accounted for higher revenue share
Based on application, global epigenetics market is segmented oncology, cardiology, immunology, and others. Oncology segment accounted for the largest market share in 2018 and is expected to grow with highest CAGR over the forecast period owing to the increasing prevalence of cancer and increasing funding from public and private sector along with the support from the government to increase the research activities are expected to grow with significant CAGR over the forecast period.
North America holds leading position in Global Epigenetics Market
PBI’s global epigenetics market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to regional analysis, North America is expected to account for larger revenue share in 2018 and the same trend is projected to follow over 2019-2025 owing to increasing activities in the region and support from the government. Presence of more number of market players in the region is the major factor drives the growth of the market over the forecast period. Asia Pacific is expected to grow with significant CAGR over the forecast period owing to increasing number of research activities in China, Japan, India and other countries of the region. Emerging market such as Brazil, India are expected to drive the growth of the market over the forecast period.
Recent Developments in the Global Epigenetics Market
- In July 2017, Agilent launched AriaDx Real-Time PCR System
- In June 2017, Illumina launched Extended RAS Panel, a NGS kit
- In January 2017, Illumina entered into an agreement with Koninklijke Philips (Netherlands) to integrate Ilumina’s sequencing systems with Philips’ IntelliSpace Genomics clinical informatics platform for oncology
Key player’s profiles in the report are Illumina (US), New England Biolabs (US), Thermo Fisher Scientific (US), Agilent (US), Abcam (UK), Active Motif (US), Merck Millipore (US), Bio-Rad Laboratories (US), QIAGEN (Netherlands), Zymo Research (US), PerkinElmer (US), and Diagenode (Belgium).
By Device Type
- Kits & Reagents
- Mass Spectrometer
- DNA Methylation
- Histone Modification
By End User
Rest of Europe
Australia & New Zealand
ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
Rest of Asia-Pacific
Rest of Latin America
Middle East and Africa (MEA)
Gulf Cooperation Council (GCC) Countries
Rest of MEA
For More Information:
Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights.
Contact Us: Shreya Paul
Senior Business Development Executive
Call @ +1-866-598-1553
Precision Business Insights Toll Free (US): +1-866-598-1553